Postęp w rozwoju szczepionek i strategiach ich stosowania w zwalczaniu chorób zakaźnych świń

• Autorzy: Pejsak Z. , Truszczynski M. , Lutnicka H.

Warianty tytułu

EN

Progress in the development of vaccines and strategies of their application in the control of infectious diseases of swine

• Języki publikacji: PL

Abstrakty

EN

Data are presented concerning vaccines used in the prophylaxis and control of some viral and bacterial infectious diseases of swine, particularly against: MPS, PRRS, PMWS CSF, AD, SI, E. coli, Cl. perfringens type C and A and oedema disease. The lower efficacy in immunization of inactivated vaccines is stressed. However in case of live vaccines against PRRS this is not always the case since also live attenuated vaccines deliver unsatisfactory results of immunization. This is explained by frequently occurring genetic changes in the genome of the field PRRSV strains in comparison with the strain or strains being in the vaccine. Vaccines against PMWS are characterized, underlining high efficacy of the vaccines in the Baculovirus system. After withdrawing from field use against CSF the vaccines Lapest and Cellpest a recombinant vaccine against CSF was introduced for control of this disease. A recombinant vaccine against AD of swine is mentioned, which was successfully used in eradication program in Europe. Of high practical value is mentioned a vaccine against SI containing subptypes H1N1, H3N2 and H1N1. Referring to vaccines against viral diseases of swine marker vaccines were mentioned enabling differentiation of animals infected from vaccinated (DIVA strategy). At the beginning of the XXI century several new and effective vaccines were developed, produced and used against diarrheal diseases of different etiology and for the first time against oedema disease. The role of strategy of vaccination depending on the characteristic of the infectious disease, the vaccine and the production system of swine is present.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2020
• Tom: 76
• Numer: 03
• Opis fizyczny: s.131-135,bibliogr.

Twórcy

autor

Pejsak Z.

• Uniwersyteckie Centrum Medycyny Weterynaryjnej UJ-UR w Krakowie, Al. Mickiewicza 24/28, 30-059 Kraków

autor

Truszczynski M.

• ul. Kaniowczyków 6, 24-100 Puławy

autor

Lutnicka H.

• Uniwersyteckie Centrum Medycyny Weterynaryjnej UJ-UR w Krakowie, Al. Mickiewicza 24/28, 30-059 Kraków

Bibliografia

• 1. Brandtzaeg P., Pabst P.: Let us go mucosal communication on slippery ground. Trends Immunol. 2004, 25, 570-577.
• 2. Durrwald R., Herwig V., Selbitz H. J.: Prufung der Schutzwirkung eines frivadenten Influenzavirus_Inaktivitat – Impsttoffes fur Schweine in Infektiosversuchen mit aktuellen Feldstammen der Subptypen H1N1, H3N2 und H1N2. Tierärztl. Praxis 2009, 37, 103-112.
• 3. Gerts V., Zakhatchouk A.: Vakzines for porcine epidemic diarrhea virus and other swine coronaviruses. Vet. Microbiol. 2017, 206, 45-51.
• 4. Maes D., Segales J., Mayns T., Sibila M., Pieters M., Haesebrouk F.: Control of Mycoplasma hyopneumoniae infections in pigs. Vet. Microbiol. 2008, 126, 297-309.
• 5. Oliver-Fernando S., Segales J., Lopes Seria S., Colen A., Merdy O.: Exploratory field study on the effect of PCV2 sow vaccination on serological, virological and reproductive parameters in a PCV2 subclinically infected sow herd. BMC Vet. Res. 2018, 16, 1196-1192.
• 6. Selbitz H. J.: Impstoffe und Impfkonzepte beim Schwein. Tierärztliche Umschau. 2019, 6, 226-230.
• 7. Truszczyński M., Pejsak Z.: Choroba obrzękowa świń z uwzględnieniem osiągniętego postępu. Med. Weter. 2014, 70, 387-390.
• 8. Truszczyński M., Pejsak Z.: Szczepionki nowej generacji. Med. Weter. 2006, 62, 855-858.
• 9. Truszczyński M., Pejsak Z.: Szczepionki przeciw kolibakteriozie prosiąt, zwłaszcza okresu poodsadzeniowego. Med. Weter. 2014, 70, 3-6.
• 10. Visser N., Lutticken D., Egger D.: Intradermal application of Aujeszkys disease strain Begonia with tocopherol-based adjuvant and a novel design injection device. Acta Vet. Hung. 1994, 42, 413-418.
• 11. Vu H. L., Pattnaik K., Osorio F. A.: Strategies to borden the cross protection efficacy of vaccines against porcine reproductive respiratory syndrome virus. Vet. Microbiol. 2017, 206, 29-34

Identyfikatory

DOI

10.21521/mw.6384